SECOND INTERNATIONAL COLLOQUIUM ON:

CARDIO-ONCOLOGY

KRAKOW, POLAND
MAY 3rd - 4th, 2018

ORGANIZED BY:
DEPARTMENT OF MEDICINE UNIT OF DRUG SCIENCES
AND CLINICAL PHARMACOLOGY CAMPUS BIO-MEDICO
UNIVERSITY OF ROME (ITALY)

ABRAMSON CANCER CENTER,
PERELMAN SCHOOL OF MEDICINE AT THE UNIVERSITY
OF PENNSYLVANIA, PHILADELPHIA, PENNSYLVANIA (US)

UNDER THE AUSPICES OF:
DEPARTMENT OF HEMATOLOGY,
JAGIELLONIAN UNIVERSITY, KRAKOW (POLAND)

POLISH NATIONAL ONCOLOGY NETWORK

POLISH SOCIETY OF ONCOLOGY

UNDER THE CO-AUSPICES OF:
JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE

Polish National Oncology Network
Dear Colleagues,

It is my great pleasure to introduce you to the Second International Colloquium on Cardio-Oncology, Krakow, May 3rd - 4th, 2018.

Cardio-Oncology is a rapidly expanding discipline that focuses on the cardiovascular performance of patients treated with anticancer drugs. It was born to oncologists and cardiologists but quickly involved hematologists, pediatricians and gerontologists, not to mention epidemiologists and preclinical scientists.

There are different approaches one may adopt in addressing cardio-oncology. Some believe that cardio-oncology should be a meticulous deciphering and listing of cardiovascular toxicities induced by anticancer drugs. This is in the focus by definition but introduces potential biases that eventually lead doctors to question benefit from some antitumor drugs. Others believe that cardio-oncology should always be guided by a thoughtful analysis of risk:benefit ratio, such that patients eventually receive optimal life-saving treatments while also receiving an adequate cardiovascular surveillance or prophylaxis. We definitely like this second approach better and that is why we invite you to attend a “Colloquium” that is conceived to be an interactive think tank. The Program is self explanatory and goes in that direction.

This Colloquium follows on the International Workshop on Anthracycline Cardiotoxicity that was held in Como back in 2006, and the First International Colloquium on Cardio-Oncology that was held in Rome, 2014. All such events were made possible by the generosity and foresight of Menarini Foundation, which I thankfully acknowledge.

I hope to see you in the historical venue of Krakow for a stimulating and enjoyable colloquium.

President of the Meeting

Prof. Giorgio Minotti
INTERNATIONAL SYMPOSIUM ON: CARDIO-ONCOLOGY
Krakow (Poland), May 3rd - 4th, 2018

ORGANIZED BY:

Giorgio Minotti
Campus Bio-Medico
University of Rome, (Italy)

President of the Meeting

Wojciech Jurczak
Department of Hematology,
Jagiellonian University, Krakow (Poland)

Local Co-Chair

Joseph R. Carver
Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania,
Philadelphia, Pennsylvania (US)

Polish Oncology and Network Leaders

Adam Maciejczyk
President of the Polish National Oncology Network
President-Elect of the Polish Society of Oncology

Stanislaw Góźdź
Vice President of the Polish National Oncology Network

Scientific Secretariat

Emanuela Salvatorelli
Pierantonio Menna

UNDER THE AUSPICES OF:

Jagiellonian University Medical College Krakow (Poland)

Polish National Oncology Network

Polish Society of Oncology

WITH AN UNRESTRICTED GRANT FROM

Fondazione Internazionale Menarini
Centro Direzionale Milanofiori
20089 Rozzano (Milan, Italy)
Edificio L – Strada 6
Phone: +39 02 55308110
Fax: +39 02 55305739
E-mail: milan@fondazione-menarini.it
Website: www.fondazione-menarini.it

PROFESSIONAL CONGRESS ORGANIZER

Congress Lab Srl
Bastioni di Porta Volta, 10
20121 Milano (Italy)
Phone: +39 02 81838672
Cell: +39 3357974061
Fax: +39 02 87181580
E-mail: fondazione@congresslab.it
www.congresslab.it

Referee:
Stefania Villanacci
stefania.villanacci@congresslab.it
Thursday, May 3rd 2018 - Morning

OPENING CONGRESS

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 a.m.</td>
<td>Arrival and registration of the participants at reception</td>
</tr>
<tr>
<td>08.30 a.m.</td>
<td>Foreword</td>
</tr>
<tr>
<td>08.45 a.m.</td>
<td>A. Casini (Florence, IT)</td>
</tr>
<tr>
<td></td>
<td>G. Minotti (Rome, IT)</td>
</tr>
</tbody>
</table>

Thursday, May 3rd 2018 - Morning

Session I – Mechanisms and clinical course of cardiovascular toxicity of cancer treatment

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.45 a.m.</td>
<td>E. Y. Yeh (Columbia, MO) Anthracyclines and nonanthracycline chemotherapeutics</td>
</tr>
<tr>
<td>09.15 a.m.</td>
<td>M. S. Ewer (Houston, TX) Anti HER2 drugs</td>
</tr>
<tr>
<td>09.45 a.m.</td>
<td>J. Moslehi (Nashville, TN) Angiogenesis inhibitors</td>
</tr>
<tr>
<td>10.15 a.m.</td>
<td>Dialogue: J. Moslehi (Nashville, TN), M. S. Ewer (Houston, TX) Emerging paradigms in cardio-oncology: immune checkpoint inhibitors</td>
</tr>
<tr>
<td>10.45 a.m.</td>
<td>Coffee break</td>
</tr>
</tbody>
</table>

Oncology

Chairpersons: G. Minotti (Rome, IT) M. Długosz-Danecka (Krakow, PL)

08.45 a.m. E. Y. Yeh (Columbia, MO) Anthracyclines and nonanthracycline chemotherapeutics

09.15 a.m. M. S. Ewer (Houston, TX) Anti HER2 drugs

09.45 a.m. J. Moslehi (Nashville, TN) Angiogenesis inhibitors

Dialogue: J. Moslehi (Nashville, TN), M. S. Ewer (Houston, TX) Emerging paradigms in cardio-oncology: immune checkpoint inhibitors

10.15 a.m. Coffee break
### Thursday, May 3\textsuperscript{rd} 2018 - Morning

**Session II – Mechanisms and clinical course of cardiovascular toxicity of cancer treatment**

**Hematology**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.15 a.m.</td>
<td>M. Breccia (Rome, IT)</td>
<td>BCR/ABL1 kinase inhibitors</td>
</tr>
<tr>
<td>11.45 a.m.</td>
<td>D. J. Lenihan (St. Louis, MO)</td>
<td>Myeloma drugs</td>
</tr>
<tr>
<td>12.15 p.m.</td>
<td>S. Szmit (Warsaw, PL)</td>
<td>Emerging paradigms in cardio-oncology: thrombosis and thromboembolism</td>
</tr>
<tr>
<td>12.45 p.m.</td>
<td>G. Minotti (Rome, IT)</td>
<td>Cautions in brief: Good drugs, wrong dosages</td>
</tr>
<tr>
<td>01.00 p.m.</td>
<td></td>
<td>Lunch</td>
</tr>
</tbody>
</table>

### Thursday, May 3\textsuperscript{rd} 2018 - Afternoon

**Session III – Cardio-Oncological management of patients**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>02.00 p.m.</td>
<td>D. M. Cardinale (Milan, IT)</td>
<td>Tuning cardio-oncological management to a continuum of early and late events</td>
</tr>
<tr>
<td>02.30 p.m.</td>
<td>A. Barac (Washington, DC)</td>
<td>Imaging: the essential and the superfluous</td>
</tr>
<tr>
<td>03.00 p.m.</td>
<td>J. P. Carver (Philadelphia, PA)</td>
<td>Primary and secondary prevention of cardiac and vascular toxicity</td>
</tr>
<tr>
<td>03.30 p.m.</td>
<td></td>
<td>Coffee break</td>
</tr>
</tbody>
</table>
**Thursday, May 3rd 2018 - Afternoon**

### Session IV – Treatment specific toxicities

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>04.00 p.m.</td>
<td>D. J. Plummer (London, UK)</td>
<td>Cardiovascular risk from hormonal agents</td>
</tr>
<tr>
<td>04.30 p.m.</td>
<td>J. Plastaras (Philadelphia, PA)</td>
<td>Cardiac complications of radiation therapy: still a problem?</td>
</tr>
<tr>
<td>05.00 p.m.</td>
<td>Dialogue: Z. Iakobishvili (Petah Tikva, IL), D. J. Lenihan (St. Louis, MO), A. Lyon (London, UK)</td>
<td>Challenging cases: from QTc prolongation to ibrutinib and atrial fibrillation</td>
</tr>
<tr>
<td>05.30 p.m.</td>
<td>B.K. Khandheria (Milwaukee, WI), J. R. Carver (Philadelphia, US)</td>
<td>What did we learn today?</td>
</tr>
<tr>
<td>06.00 p.m.</td>
<td></td>
<td>End of the day/ Welcome cocktail</td>
</tr>
</tbody>
</table>

**Thursday, May 4th 2018 - Morning**

### Session V – Cardio-Oncology in clinical studies and real life

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 a.m.</td>
<td>S. Dent (Ottawa, CA)</td>
<td>Cardio-Oncology networks for patients</td>
</tr>
<tr>
<td>09.00 a.m.</td>
<td>T. Suter (Bern, CH)</td>
<td>Strengths and weaknesses of cardiac surveillance in clinical trials</td>
</tr>
<tr>
<td>09.30 a.m.</td>
<td>G. Minotti (Rome, IT)</td>
<td>Clinical studies with a real life approach: an Italian experience</td>
</tr>
<tr>
<td>10.00 a.m.</td>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>10.30 a.m.</td>
<td></td>
<td>Coffee break</td>
</tr>
</tbody>
</table>
Thursday, May 4<sup>th</sup> 2018 - Morning

**Session VI – Cancer survivors**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00 a.m.</td>
<td><strong>E. Howard</strong> (Detroit, MI)</td>
<td>My life as a cancer survivor</td>
</tr>
<tr>
<td>11.10 a.m.</td>
<td><strong>R. M. Steingart</strong> (New York, NY)</td>
<td>Follow up of adult cancer survivors: how and how often</td>
</tr>
<tr>
<td>11.40 a.m.</td>
<td><strong>G. Armstrong</strong> (Memphis, TN)</td>
<td>Chronic health conditions in childhood cancer survivors</td>
</tr>
<tr>
<td>12.10 p.m.</td>
<td><strong>F. Lo Coco</strong> (Rome, IT)</td>
<td>Emerging paradigms in cancer survivorship: what do we know about early and late effects of new cancer therapies?</td>
</tr>
<tr>
<td>12.40 p.m.</td>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>01.00 p.m.</td>
<td></td>
<td>Lunch</td>
</tr>
</tbody>
</table>

Thursday, May 4<sup>th</sup> 2018 - Afternoon

**Session VII – Helping the cardio-oncologist: From real life to guidelines**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>02.30 p.m.</td>
<td><strong>J. R. Carver</strong> (Philadelphia, PA)</td>
<td>The ASCO guideline and the ESC position paper</td>
</tr>
<tr>
<td>03.00 p.m.</td>
<td><strong>S. Armenian</strong> (Duarte, CA)</td>
<td>Would guidelines help in real life?</td>
</tr>
<tr>
<td>03.30 p.m.</td>
<td><strong>M. Ewer</strong> (Texas, IT), <strong>W. Jurczak</strong> (Krakow, PL)</td>
<td>Take home messages and preparing for Conference Report</td>
</tr>
<tr>
<td>04.00 p.m.</td>
<td><strong>G. Minotti</strong> (Rome, IT)</td>
<td>Concluding remarks</td>
</tr>
</tbody>
</table>
Meeting venue
The venue for the Meeting will be “..............................”
– ..................................................Krakow (Poland)

Secretariat during the Meeting
The Secretariat will be open at the following times:
Thursday, May 3rd 2018 from 08.00 p.m. to 07.00 p.m.
Friday, May 4th 2018, from 08.00 a.m. to 06.00 p.m.

Official language
The official language of the Meeting will be English

ECM

EACCME

Registration
The Meeting is free to attend. Please confirm the participation to the Organizing Secretariat
(Fondazione Internazionale Menarini – Phone: +39 02 55308110 – Fax: +39 02 55305739.
E-mail: milan@fondazione-menarini.it) within

Technical facilities
Facilities will be available for computer presentations and overhead projections.
A business center with PC (Powerpoint for Windows) will be available for check and preview of presentations. It is essential that speakers take their presentation to the business center at least one hour before the session starts.
The center will be open at the following times:
Thursday, May 3rd 2018, from 05.00 p.m. to 07.00 p.m.
Friday, May 4th 2018, from 08.00 a.m. to 06.00 p.m.
Saturday, May 5th 2018, from 08.00 a.m. to 01.00 p.m.

Lunches and coffee breaks
Lunches and coffee breaks will be served in the Meeting area

Abstracts book
Participants will receive the Abstract book at the Meeting.
Armenian Saro
Armstrong Gregory
Barac Ana
Breccia Massimo
Cardinale Daniela Maria
Carver Joseph R.
Dent Susan
Długosz-Danecka Monika
Ewer Michael S.
Gennari Alessandra
Howard Emily
Iakobishvili Zaza
Jurczak Wojciech
Khandheria Bijoy K.
Lenihan Daniel J.
Lo Coco Francesco
López-Fernández Teresa
Lyon Alexander
Menna Pierantonio
Minotti Giorgio
Moslehi Javid
Opolski Grzegorz
Plastaras John
Plummer Chris J.
Salvatorelli Emanuela
Steingart Richard M.
Suter Thomas
Szmit Sebastian
Tito Fojo Antonio
Torbicki Adam
Tweardy David J.
Yeh Edward T.
For more information and for the registration to the Congress, visit the following website:

www.fondazione-menarini.it